Skip to main content
. 2013 Sep 11;2013(9):CD004289. doi: 10.1002/14651858.CD004289.pub5

Angel 2007.

Methods

  • Study design: double‐blinded cross‐over RCT

  • Time frame: NR

  • Follow‐up period: 2 months
Participants

  • Country: Mexico

  • Setting: NR

  • Inclusion criteria: CAPD patients without present or past (3 months) evidence of inflammation or anti‐inflammatory drug intake (including statins or NSAIDs)

  • Age (mean ± SD) years: 54 ± 12 years

  • Sex: NR

  • Exclusion criteria: NR
Interventions Treatment group

  • Pravastatin

    • Dose: 20 mg daily

    • Treatment duration: 2 months


Control group

  • Placebo
Outcomes

  • BMI

  • Creatinine

  • TC, LDL

  • TG

  • IL‐6, CRP
Notes Abstract only publication
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence generation (selection bias) Unclear risk NR
Allocation concealment (selection bias) Unclear risk NR
Blinding of participants and personnel (performance bias) 
 All outcomes Low risk Double‐blinded
Blinding of outcome assessment (detection bias) 
 All outcomes Unclear risk NR
Incomplete outcome data (attrition bias) 
 All outcomes Unclear risk NR
Selective reporting (reporting bias) High risk Published reports did not include all expected outcomes
ITT analysis Unclear risk NR